Browse TNC

Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix.
Domain PF07974 EGF-like domain
PF00147 Fibrinogen beta and gamma chains
PF00041 Fibronectin type III domain
Function

Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumors, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells (PubMed:19884327).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001655 urogenital system development
GO:0001763 morphogenesis of a branching structure
GO:0003401 axis elongation
GO:0007162 negative regulation of cell adhesion
GO:0007528 neuromuscular junction development
GO:0007584 response to nutrient
GO:0009612 response to mechanical stimulus
GO:0009991 response to extracellular stimulus
GO:0014012 peripheral nervous system axon regeneration
GO:0022612 gland morphogenesis
GO:0030198 extracellular matrix organization
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030850 prostate gland development
GO:0031099 regeneration
GO:0031102 neuron projection regeneration
GO:0031103 axon regeneration
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0031670 cellular response to nutrient
GO:0032526 response to retinoic acid
GO:0033273 response to vitamin
GO:0033280 response to vitamin D
GO:0034694 response to prostaglandin
GO:0035239 tube morphogenesis
GO:0042475 odontogenesis of dentin-containing tooth
GO:0042476 odontogenesis
GO:0043062 extracellular structure organization
GO:0045471 response to ethanol
GO:0048608 reproductive structure development
GO:0048678 response to axon injury
GO:0048732 gland development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0050808 synapse organization
GO:0060425 lung morphogenesis
GO:0060441 epithelial tube branching involved in lung morphogenesis
GO:0060447 bud outgrowth involved in lung branching
GO:0060512 prostate gland morphogenesis
GO:0060541 respiratory system development
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060602 branch elongation of an epithelium
GO:0060638 mesenchymal-epithelial cell signaling
GO:0060739 mesenchymal-epithelial cell signaling involved in prostate gland development
GO:0060740 prostate gland epithelium morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061458 reproductive system development
GO:0061564 axon development
GO:0071229 cellular response to acid chemical
GO:0071295 cellular response to vitamin
GO:0071300 cellular response to retinoic acid
GO:0071305 cellular response to vitamin D
GO:0071379 cellular response to prostaglandin stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071496 cellular response to external stimulus
GO:0071774 response to fibroblast growth factor
GO:0071798 response to prostaglandin D
GO:0071799 cellular response to prostaglandin D stimulus
GO:0097305 response to alcohol
Molecular Function GO:0045545 syndecan binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0005614 interstitial matrix
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0044420 extracellular matrix component
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
Reactome R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-216083: Integrin cell surface interactions
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-3000170: Syndecan interactions
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNC and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20622113GlioblastomaInhibit immunity (infiltration)Knocking down the tenascin-C gene using the short hairpin RNA strategy converted glioma cells to a transmigration-permissive phenotype for Jurkat cells regarding ERK activation, transmigration, and amoeba-like shape formation. In addition, exogenous tenascin-C protein reduced the amoeba-like shape formation and transmigration of Jurkat cells through MCF-7 and HepG2 cell monolayers.
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3010.644
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5110.841
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1360.938
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6440.296
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1530.695
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0130.998
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.980.202
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0240.632
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.0050.662
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3780.817
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2020.585
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4940.0396
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.29.612.60.107
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.211.910.30.33
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117195.913.10.355
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.19.1140.596
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382718.4018.40.0356
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614250250.103
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNC
Nametenascin C
Aliases MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location9q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.